http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Guidewire PartnerConnect Ecosystem Surpasses 110 Cloud-Native Integrations, Enables Insurers to Accelerate Business Growth and Unlock New Opportunities
-
Growing Number of Industries Embracing Commercial Drone Operations as Demand Skyrockets
-
One-Hour Payouts: Hola Prime Solves Prop Trading's Biggest Problem
-
One-Hour Payouts: Hola Prime Solves Prop Trading's Biggest Problem
-
Auri and Hollywall Form New Crypto Currency
-
Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot's Operations
-
NashBio Announces New Suite of Strategic Data Solutions to Accelerate Life Science Research and Development
-
Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot's Operations
-
Ethema Completes Acquisition of Kentucky Treatment Operations
-
Palvella Therapeutics (PVLA) Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations in the Jour
-
BTCS Launches Innovative Staker Protection Plan
-
Avantor® to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025
-
Chemify Hires Biopharma Veteran Dr. Alastair Leighton as Chief Operating Officer
-
Cellebrite to Report Fourth-Quarter and Fiscal Year 2024 Financial Results on February 13, 2025
-
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
-
PAR Technology Corporation to Participate at the 27th Annual Needham Growth Conference
-
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
-
Totus Medicines Announces Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial Evaluating TOS-358, a Covalent PI3Ka Selective Therapy for the Treatment of Sele
-
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
-
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
-
Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter
-
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformati
-
Thumzup Media Corporation Offers $10,000 in Credits for Small Businesses to Support Recovery Efforts Following Los Angeles Wildfires
-
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
-
First Phosphate Reports University Research Reports Relating to the Geological Characterization of its Three Bégin-Lamarche Phosphate Zones
-
Cooler Master Launches the CH351: 3D Surround Sound Wireless Gaming Headset for Total Immersion
-
Immunocore (IMCR) announces strategic priorities
-
Becton Dickinson (BDX) names Pamela Spikner CAO and controller
-
MD Logic Health® Introduces Cool: A Breakthrough In Women's Hormonal Health!
-
Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine
-
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
-
Constellation Energy (CEG) to Acquire Calpine for $16.4 Billion in Cash and Stock
-
Constellation To Acquire Calpine; Creates America’s Leading Producer of Clean and Reliable Energy to Meet Growing Demand for Customers and Communities
-
BD Names Pamela Spikner as Chief Accounting Officer and Controller
-
Fineqia Ltd Reports 38.4% Increase in Digital Asset Blockchain Infrastructure AMC's Year-End Net Asset Value
-
Leads Sniper Offers Web Scraping Tools, Empowers Businesses to Scrape Valuable Leads
-
Fishat Prepares for $FHAT Presale on January 10 with Solidproof Audit and KYC
-
WOLF FINAL DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Wolfspeed, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 17 Deadline in Securities Class
-
PACS DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages PACS Group Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important January 13 Deadline in Securities Class Action - P
-
HAS DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Hasbro, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important January 13 Deadline in Securities Class Action - HAS
-
ASML DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ASML Holding N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 13 Deadline in Securities Class Action
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Customers Bancorp, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - CUBI
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Joint Stock Company Kaspi.kz Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - KSPI
-
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Southwest Airlines Co. - LUV
-
TOP RANKED ROSEN LAW FIRM Encourages Western Asset Management Company LLC Mutual Fund Investors to Inquire About Securities Class Action Investigation - LAOIX, WATFX, WACPX
-
ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
-
CMG DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Chipotle Mexican Grill, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 10 Deadline in Securities Cl
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Match Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MTCH
-
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate


